The 29th annual JP Morgan Healthcare Conference was held in San Francisco, CA from January 10-13, 2011. A list of events and catalysts that were announced or updated at the conference is included in this report.

Key catalysts included in JP Morgan coverage:

• Bydureon (AMLN, ALKS, LLY) tQT study to initiate in the first quarter and will complete by the end of year to allow for filing of a response to the CRL by year end
• LymphoStat-B subQ (HGSI, AZN, GSK) for SLE to enter Phase III in 2011
• An sBLA filing for VEGF Trap-Eye (REGN, Bayer) in central retinal vein occlusion expected in the second half of 2011
• Data from the remaining Phase III program for dapagliflozin (BMY, AZN) for type 2 diabetes expected at 2011 ADA meeting (June 24-28)
• Phase II Hepatitis C data on BMS-790052, BMS-650032 and PEG-Interferon lambda (BMY) expected at 2011 EASL (March 30 – April 3) or AASLD (November 4-8) meetings
• An NDA filing for oral INCB18424 (INCY, NVS) in myeloproliferative disorders planned for the second quarter of 2011 with an FDA advisory panel meeting anticipated in the second half of 2011
• Results from the confirmatory, PRE-SURGE II, and supporting safety, RE-SURGE, Phase III studies of Arcalyst (REGN) anticipated in the first quarter of 2011
• Initiation of a confirmatory Phase III study of Folotyn (ALTH, IDIS) for NHL expected during the first half of 2011
• Response to Non-Approvable Letter for Firazyr (SHPGY, SNY) in HAE expected in the first half of 2011, possibly the first quarter
• Top line data from the Phase III ARISTOTLE study of Eliquis (BMY, PFE) for SPAF expected during mid-2011
• Data from Phase III SERAPHIN study of macitentan in PAH expected in the fourth quarter of 2011

For the list of catalysts in Excel, please contact Bobbi Sue Richardson at (858) 200-2390 or email clientservices@pharmaintel.informa.com.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.